Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.34 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.34 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211566 | 0.78 | CA1 (0.31) | — | |
| SCHEMBL28491723 | 0.69 | CA4 (0.34) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL14835811 | 0.69 | CYP2C9 (0.38) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL8743661 | 0.67 | LTA4H (0.32) | CA4 | |
| SCHEMBL28818192 | 0.67 | NPC1 (0.43) | — | |
| SCHEMBL2475622 | 0.66 | ORAI1 (0.48) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL28487737 | 0.66 | ORAI1 (0.38) | CA4CA6CA5ACA7ENPP2 | |
| SCHEMBL16087859 | 0.66 | LMNA (0.44) | — | |
| SCHEMBL11822724 | 0.65 | LMNA (0.42) | — | |
| SCHEMBL15326555 | 0.64 | KDM4C (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451782-B1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9216970-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9181206-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150105392-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-16 | — | — | US | disclosed |
| US-8946233-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2250168-B1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8822522-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140194426-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140135333-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8664227-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-5310929-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | disclosed |
| US-5310928-A | Process for preparing biphenyltetrazole compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | disclosed |
| WO-1994003435-A1 | PRODRUGS OF IMIDAZOLE CARBOXYLIC ACIDS AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-02-17 | — | — | WO | disclosed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | disclosed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | disclosed |
| US-5206374-A | Process for preparing tetrazolylphenylboronic acid intermediates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
| US-5206374-A | Process for preparing tetrazolylphenylboronic acid intermediates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
| US-5130439-A | Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists | E.I. DU PONT DE NEMOURS AND COMPANY, A CORPORATION OF DELAWARE | 1992-07-14 | — | — | US | disclosed |
| US-5130439-A | Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists | E.I. DU PONT DE NEMOURS AND COMPANY, A CORPORATION OF DELAWARE | 1992-07-14 | — | — | US | disclosed |
| US-5130439-A | Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists | E.I. DU PONT DE NEMOURS AND COMPANY, A CORPORATION OF DELAWARE | 1992-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135333-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | REN, AGTR1, AGTR2 | CA4 2158/4885CA6 1795/4885CA5A 1650/4885 |
| US-20140194426-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | CA4 1437/4885CA6 1850/4885CA5A 1237/4885 |
| US-20150105392-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | REN, AGTR1, AGTR2 | CA4 2158/4885CA6 1795/4885CA5A 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.